Rua Bioscience Ltd 2021 AR2
The report highlights Rua Bioscience's transformational fiscal year 2021, marked by its successful listing on the NZX as the first company founded by a Māori community. The company advanced its global export strategy by signing an exclusive sales agreement with Germany's Nimbus Health and completing its first trial export. Rua also progressed toward GMP certification for its Gisborne manufacturing facility and Mangaoporo cultivation center. Additionally, the company launched a ground-breaking research program with the University of Waikato to develop hyperspectral imaging technology for real-time cannabis crop assessment.
Company: Rua Bioscience Ltd
Sector: Manufacturing
Country: New Zealand
Year: 2021
Type: AR2
Pages: 124
Back to company
Rua Bioscience Ltd
Annual Report
The report highlights Rua Bioscience's transformational fiscal year 2021, marked by its successful listing on the NZX as the first company founded by a Māori community. The company advanced its global export strategy by signing an exclusive sales agreement with Germany's Nimbus Health and completing its first trial export. Rua also progressed toward GMP certification for its Gisborne manufacturing facility and Mangaoporo cultivation center. Additionally, the company launched a ground-breaking research program with the University of Waikato to develop hyperspectral imaging technology for real-time cannabis crop assessment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jul 1, 2020 - Jun 30, 2021
Fiscal Year
2021
Published
Sep 17, 2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees